A Phase 4 interventional study of pressure stockings and Midodrine in Intradialytic Hypotension, sponsored by Nimedical. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-15.
Sponsored by Nimedical · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing midodrine in Hypotension — 4 open to participants now, 4 under way, 1 of them phase 3. Midodrine · Hypotension.
Among the 12 studies testing midodrine in Hypotension, this one is the 9th largest by planned enrollment, is the only one that started in 2016, is one of 4 in phase 4, and was the 6th registered.
887 studies on the registry are indexed under Hypotension; 196 are open to participants now.
Browse Hypotension studies →4 of the 12 studies testing midodrine in Hypotension are open now, in 2 countries. Recruiting first, the newest first:
Ottawa Heart Institute Research Corporation · Sites in Canada
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
James J. Peters Veterans Affairs Medical Center · Sites in United States
Ages 18–60
Sohag University
Ages 18–35 · Women only · Healthy volunteers
By country, each count listing its studies:
Midodrine: first FDA approval 1996 (PROAMATINE). What it is approved for, and how studies give it, is on its page →
Of the 111 Hypotension studies recruiting now, 50 (45%) set no upper age limit and 36 (32%) stop at 75 or younger; 7 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 3 · Phase 4 4
First in 2011; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 35 is below the median of 87 across 590 interventional studies indexed under Hypotension.
Median enrollment 62 across the 12 interventional studies. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 12 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Nimedical as lead sponsor.
Nimedical has 1 study filed under Hypotension — fewer than ten, so there is no comparison to draw.
1 of the studies testing midodrine in Hypotension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05839652James J. Peters Veterans Affairs Medical CenterTreatment of Orthostatic Hypotension in SCI | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing midodrine in Hypotension, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a research study to test the application of FDA-approved, non-invasive device (NICaS) that measure the performance of your heart during HD treatment.
The incidence of intradialytic hypotension (IDH) events, reported to occur in 15% to 50% of hemodialysis (HD) treatments, is still high despite major technical advances in HD technology. By definition, excessive reduction in intravascular volume by ultrafiltration and limited vascular refilling from tissues into the vascular space is the cause of IDH. Chronic HD patients exhibit a high prevalence of peripheral vascular and cardiac abnormalities. Specifically, hemodynamic instability during HD can occur due to insufficient reduction in venous unstressed volume, poor diastolic filling under reduced atrial pressures associated with diastolic dysfunction, altered cardiac contractility, and impaired vascular reactivity. An IDH event can lead to myocardial cerebral and other organ ischemia. Long- and short-term adverse outcomes have been associated with IDH, a common HD complication and significant cause of morbidity.
Recent pilot studies suggest that in IDH-prone subjects, measurements of hemodynamic variables during HD can be used to categorize the hemodynamic response into three subgroups: cardiac power index (CPI) reduction with stable total peripheral resistance (TPR), TPR reduction with stable CPI, and reduction in TPR and CPI groups. It is hypothesized that targeted intervention for each subgroup can reduce IDH.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
pressure stockings worn during dialysis treatment
Device: pressure stockings
Midodrine before dialysis treatment
Drug: Midodrine
pressure stocking and Midodrine
Other: pressure stockings and midodrine
pressure stockings worn during dialysis throughout treatment period
administered Midodrine before each dialysis treatment during treatment period based on PI's judgement. Including consideration of blood pressure.
combination of Midodrine and pressure stocking before each dialysis treatment throughout treatment period
Hypotension
Post dialysis BP measured in mm/Hg
Time frame: 6 weeks
Weight
Post dialysis weight measure in kg
Time frame: 6 weeks
Cardiac Index
Cardiac Index results from NICaS results vs Echocardiogram results measured in L/min/m2
Time frame: 1 week
No study locations are listed for this record.
Plan to share: No — There is no current plan to share IPD with other researchers
No publications or documents are linked to this record.
Started Nov 2016 (actual). Primary completion is estimated for Apr 2017, 4 months after the start.
Of 61 phase 4 interventional studies under Hypotension, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's planned 4 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Midodrine